I think the tie up with Promega, the move into Therapeutics, and the exosome space in general will see this company substantially re-rated this year.
Sure, a capital raise is likely.....and knowing David Williams he'd probably like to increase his exposure....but even with that occurring, the stock could easily reach a $200mln mkt cap this year.
If you're waiting for the cap raise, you may miss the ride.
IIQ General Discussion, page-218
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.16M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 48.0¢ | 47.5¢ | $12.31K | 25.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6367 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.0¢ | 8024 | 2 |
View Market Depth
| Last trade - 15.59pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
48.0¢ |
Change
0.000 ( 2.04 %) |
||||
| Open | High | Low | Volume | ||
| 48.0¢ | 48.0¢ | 47.0¢ | 6711 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| IIQ (ASX) Chart |